Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11273216-B2
Publication Date
2022-03-15
Expiration Date
Abstract
The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
Core Innovation
The invention relates to a universal influenza vaccine concept that uses influenza-derived peptides comprising CD8+ T cell epitopes and, optionally, CD4+ T cell epitopes, together with B cell epitopes such as M2e. The peptides are immobilized or attached to nanoparticles to present the epitopes for immune recognition, and the design combines humoral and cellular immunity to support broad protection.
A central aspect is the use of conserved cross-strain CD8+ T cell epitope sets intended to promote cross-subtype reactivity. The document further specifies a universal B cell epitope, including M2e (matrix 2 ectodomain), and describes B cell receptor engagement in the context of M2e-specific responses.
In the nanoparticle presentation, the peptide is attached to a gold glyconanoparticle, and the glyconanoparticle further comprises ligands with a carbohydrate moiety selected from glucose, N-Acetylglucosamine (GlcNAc), and 2′-thioethyl-β-D-glucopyranoside variants. The document states that nanoparticle features provide immune danger signals and APC targeting, which are positioned to reduce or eliminate the need for conventional adjuvant.
Claims Coverage
The independent claims cover a vaccine composition with influenza virus peptides containing specified CD8+ T cell epitopes attached to a gold glyconanoparticle bearing defined carbohydrate ligands. The dependent claims further define linker attachment, multiple distinct CD8+ T cell epitopes, optional CD4+ T cell epitope presentation, and interaction with at least two different HLA supertypes.
Gold glyconanoparticle-attached CD8+ T cell epitope peptide composition with defined carbohydrate ligands
A vaccine composition comprising an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 21, wherein the peptide is attached to a gold glyconanoparticle, and wherein the glyconanoparticle further comprises one or more ligands comprising a carbohydrate moiety selected from the group consisting of glucose, N-Acetylglucosamine (GlcNAc), 2′-thioethyl-β-D-glucopyranoside, and 2′-thioethyl-D-glucopyranoside.
Linker-mediated attachment of CD8+ T cell epitope peptide to a nanoparticle
The vaccine composition covers a CD8+ T cell influenza virus peptide attached to the nanoparticle via a linker.
Multiple distinct CD8+ T cell epitopes in a peptide composition
The vaccine composition includes two or more influenza virus peptides each containing a different CD8+ T cell epitope.
Selection of CD8+ T cell epitopes from SEQ ID NOs 1 to 21
The vaccine composition covers two or more influenza virus peptides selected from the peptides set out in SEQ ID NOs: 1 to 21.
Optional CD4+ T cell epitope peptide presentation on nanoparticles
The vaccine composition covers a CD4+ T cell epitope influenza virus peptide attached to a nanoparticle, optionally specifying nanoparticle material (gold, calcium phosphate, or silicon) and optionally attaching via a linker.
Immunogenic peptide interaction with at least two HLA supertypes
The vaccine composition comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.
Overall, the claim set is centered on a vaccine composition in which influenza-derived immunogenic peptides containing specified CD8+ T cell epitopes are presented via attachment to a gold glyconanoparticle displaying defined carbohydrate moieties, with dependents further specifying linker attachment, peptide multiplicity, optional CD4+ epitope inclusion, and enhanced breadth by requiring interaction with multiple HLA supertypes.
Stated Advantages
The design combines humoral and cellular immunity to support broad protection.
Cross-strain CD8+ T cell epitope sets are intended to promote cross-subtype reactivity.
Nanoparticle features provide immune danger signals and APC targeting.
The nanoparticle features are positioned to reduce or eliminate the need for conventional adjuvant.
Documented Applications
Universal influenza vaccine concept.
Interested in licensing this patent?